Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?

US Lazertinib Decision A Catalyst

 
• By Jung Won Shin
  
signs of recovery
Korean firms Opt For Rights Offerings Amid Shoots of recovery in funding • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Focus On Asia